EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of Efficacy of Oral Tofacitinib Versus Oral Minoxidil in Patients with Alopecia Areata

Raaza Malja, Aisha Ghias, Zunaira Arshad, Wajeeha Nusrat, Zahida Rani

Indus Journal of Bioscience Research · 30.06.2025 · 3 (6) · 1472-1476

DOI: 10.70749/ijbr.v3i6.3199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indus Journal of Bioscience Research, online erschienen am 30.06.2025. Verfasst von Raaza Malja und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Alopecia areata is a common autoimmune condition characterized by non-scarring hair loss with variable clinical outcomes. Emerging therapies such as Janus kinase (JAK) inhibitors, including tofacitinib, have shown promising results, while oral minoxidil is increasingly being used as an alternative. This study compared the efficacy of oral tofacitinib versus oral minoxidil in patients with alopecia areata. Methodology: This comparative experimental study was conducted in the Dermatology Unit-II, Mayo Hospital, Lahore, from October 2024 to April 2025. A total of 58 patients clinically diagnosed with alopecia areata were included by consecutive non-probability sampling and divided into two groups: Group A received oral tofacitinib 5 mg twice daily, and Group B received oral minoxidil 0.25 mg twice daily, for 12 weeks. Disease severity was assessed using the Severity of Alopecia Tool (SALT) score at baseline and 12 weeks. Efficacy was defined as ≥50% reduction in SALT score. Data were analyzed using SPSS v25.0, with Chi-square test applied and p ≤ 0.05 considered significant.

Results

Baseline demographic and disease characteristics were comparable between groups. Efficacy was achieved in 86.2% of patients in the tofacitinib group compared to 62.1% in the minoxidil group (p=0.036). Mean SALT score reduction was significantly greater in the tofacitinib group (65.29 ± 13.03%) than in the minoxidil group (50.15 ± 13.36%) (p = 0.002).

Conclusion

Oral tofacitinib demonstrated superior efficacy compared to oral minoxidil in patients with alopecia areata, achieving greater reduction in disease severity and higher treatment response rates.

Zitieren

APA

Malja, R., Ghias, A., Arshad, Z., Nusrat, W., & Rani, Z. (2025). Comparison of Efficacy of Oral Tofacitinib Versus Oral Minoxidil in Patients with Alopecia Areata. Indus Journal of Bioscience Research, 3(6), 1472-1476. https://doi.org/10.70749/ijbr.v3i6.3199

Vancouver

Malja R, Ghias A, Arshad Z, Nusrat W, Rani Z. Comparison of Efficacy of Oral Tofacitinib Versus Oral Minoxidil in Patients with Alopecia Areata. Indus Journal of Bioscience Research. 2025;3(6):1472-1476. doi:10.70749/ijbr.v3i6.3199

BibTeX
@article{Malja2025,
  author = {Malja, Raaza and Ghias, Aisha and Arshad, Zunaira and Nusrat, Wajeeha and Rani, Zahida},
  title = {Comparison of Efficacy of Oral Tofacitinib Versus Oral Minoxidil in Patients with Alopecia Areata},
  journal = {Indus Journal of Bioscience Research},
  year = {2025},
  volume = {3},
  number = {6},
  pages = {1472--1476},
  doi = {10.70749/ijbr.v3i6.3199}
}
Kostenlos starten →